Atezolizumab (Tecentriq): Uses, Cost and Side Effects

Atezolizumab is a monoclonal antibody that binds PD-L1, a protein sitting on tumour cells and on immune cells inside the tumour. It blocks PD-L1 from pairing with PD-1 and with B7.1 on T cells. Those pairings normally switch the T cell off. Blocking them aims to let the immune system recognise and attack the cancer itself.

Atezolizumab is the generic name of the molecule. Tecentriq is the brand it is sold under, made by Roche. They are the same medicine.

Two things follow from the mechanism. First, atezolizumab does not attack cancer cells directly the way chemotherapy does. It works only where a person still has T cells able to respond, which is why it helps in a proportion of patients rather than in everyone who receives it. Second, releasing a brake on the immune system can let that system turn on healthy organs. That is where immune-related adverse events come from, and it is covered further down this page.

Class and mechanism descriptions here follow the standard oncology references used by NCCN, ASCO and ESMO in their patient-facing material, together with the manufacturer’s approved product information.

They work on the same pathway from opposite ends. Pembrolizumab and nivolumab are PD-1 inhibitors and block the receptor on the T cell. Atezolizumab is a PD-L1 inhibitor and blocks the protein on the tumour side of the same handshake.

This is the part almost every search result skips, because most patient pages treat all checkpoint inhibitors as one thing. They are one family, but the target is not the same, and the approved uses differ substantially as a result.

Atezolizumab is not approved for cancer in general. It is cleared for a defined list of cancers and settings, each assessed separately by the regulator. Within each of those, only certain stages, biomarker results or prior-treatment histories qualify.

Its centre of gravity is lung, liver and bladder cancer. That is a genuinely different footprint from pembrolizumab, and it is the main practical reason one drug appears on a prescription rather than the other.

On Indian regulatory status: the intravenous form of atezolizumab is marketed in India by Roche Products India. In August 2025 the Indian regulator cleared Roche to import and market a subcutaneous form of atezolizumab, with a Phase IV study condition attached (reported by The Economic Times, 12 August 2025), and Roche launched that form in India in May 2026 (reported by The Pharma Letter, 18 May 2026). Regulatory status is decided indication by indication and moves over time, so any specific use should be confirmed against the current CDSCO-approved label rather than taken from a page like this one.

Atezolizumab is usually given as an intravenous infusion in a day-care oncology unit. Common schedules are 1200 mg every three weeks, 840 mg every two weeks, or 1680 mg every four weeks. The first infusion typically runs over about 60 minutes, and later ones over about 30 minutes if the first was tolerated.

It is not a tablet and it cannot be taken at home. The dose is flat, set by the schedule rather than calculated from body weight, which is unusual among cancer drugs and has a direct effect on cost.

1. Before the cycle — blood tests check thyroid, liver, kidney and blood-count values, and you are asked about any new symptom since the last cycle. Results can delay a cycle. That is routine caution, not a setback.
2. Review — the oncologist confirms the dose and that it is safe to proceed that day.
3. The infusion — a cannula is placed and the drug runs in. No sedation is needed, and hair loss is not expected from this drug itself.
4. Short observation — a period of monitoring for infusion reactions, longer after the first dose.
5. Between cycles — you watch for new symptoms and report them promptly. Immune side effects can appear weeks or months after a dose, and even after treatment has stopped.

The subcutaneous option. A subcutaneous injection form of atezolizumab, given into the thigh in roughly seven minutes rather than through a drip, was cleared by India’s regulator in August 2025 and launched in India in May 2026. It shortens chair time considerably. It is the same molecule and carries the same immune-related risks, so it changes the logistics of a cycle rather than the safety conversation around it. Whether it is available at a given centre, and whether it suits a given indication, is a question for the treating team.

How long treatment continues varies. In many advanced-disease settings it continues while it appears to be working and is tolerated, reviewed at each scan. It stops earlier if the cancer progresses, if a serious immune-related event develops, or if the person chooses to stop.

The commonest reported effects are fatigue, reduced appetite, nausea, cough and breathlessness. The characteristic risks are immune-related adverse events, where the immune system attacks a healthy organ. Most are manageable when caught early. A few are medical emergencies.

Immune-related events are defined as much by when they appear as by what they are. That is why the pre-cycle blood tests continue for the whole course, and why a symptom weeks after a dose still counts.

Symptoms that need urgent assessment, not home management: new or worsening breathlessness or a persistent dry cough; loose motions that increase in number or contain blood; chest pain or palpitations; severe unexplained fatigue with dizziness, vomiting or collapse; yellowing of the eyes or skin. For any of these, contact your treating oncology team immediately or go to the nearest emergency department. Do not self-medicate and do not wait for the next scheduled cycle. Tell any doctor who sees you, in any department, that you are on immunotherapy — it changes how these symptoms are investigated.

Where atezolizumab is combined with bevacizumab for liver cancer, the combination adds its own considerations, including blood pressure, protein in the urine and bleeding risk. Screening for oesophageal varices before starting is standard in that setting.

Detailed, symptom-by-symptom guidance sits on the dedicated side-effect pages rather than here. This page is an orientation to the medicine, not a triage tool.

Indian retail pharmacy listings such as Tata 1mg have publicly displayed a maximum retail price of roughly ₹3.39 lakh for one 1200 mg vial, with listed selling prices somewhat lower (indicative, as of August 2026). That is a published retail figure, not a CION price. No rate is published here against this molecule.

Four things decide what a course actually costs, and the vial price is only the first.

• The dose is flat, not weight-based — 1200 mg every three weeks is 1200 mg whether the patient weighs 50 kg or 90 kg. With weight-dosed drugs a smaller patient pays less per cycle. Here they do not. This single fact surprises most families and is worth knowing before the first estimate.
• The number of cycles — the real multiplier. Treatment often continues while it is working and tolerated, so a course is open-ended in many settings rather than a fixed package.
• Everything around the infusion — day-care charges, the pre-cycle blood tests, the consultation, and response-assessment imaging between cycles. Response-assessment PET-CT is generally coordinated at partner imaging centres rather than done inside the treating unit, so it is billed separately.
• The combination partner — atezolizumab is frequently given with something else: carboplatin and etoposide in small-cell lung cancer, bevacizumab in liver cancer. That second drug carries its own cost and its own monitoring.

No biosimilar yet. There is no approved atezolizumab biosimilar in India as of August 2026. That is a real difference from nivolumab, whose Indian patent lapsed in May 2026 and for which a domestic biosimilar launched in January 2026 at roughly a quarter of the reference price (indicative, as of August 2026). The cost gap between molecules is not a reason to ask for a switch. Which drug applies is set by the diagnosis and the label, not by the price list.

Scheme and insurance cover. Coverage of checkpoint inhibitors under state schemes such as Aarogyasri, and under private insurance policies, varies by policy, by package and by indication. Ask for the position in writing before the first cycle rather than after it, and ask specifically whether the drug, the day-care charge and the imaging are each covered. Any figure quoted anywhere, including here, is indicative as of August 2026 and changes.

An authenticity note, not a sales one: counterfeit checkpoint inhibitors have been reported entering the Indian market. Insist that any vial is dispensed through a licensed hospital pharmacy with documented cold-chain handling at 2–8°C, and keep the batch documentation. A patient-support programme for this medicine has been publicly listed in India; the prescribing doctor can confirm whether one applies and on what terms.

If the prescription names the other PD-L1 inhibitor, Durvalumab (Imfinzi): Uses, Cost and Side Effects is the matching explainer and is the drug most often compared with atezolizumab in lung cancer. If the comparison you actually need is against the PD-1 side, Pembrolizumab vs Atezolizumab sets the two side by side.

If the prescription in your hand has words on it you cannot place — a molecule name, a brand name, a dose in milligrams and a cycle interval — Reading Your Prescription: What the Drug Name and Dose Mean decodes it line by line. For an Indian-made monoclonal antibody used in a very different setting, and a useful contrast in cost and class, see Nimotuzumab (BioMab EGFR): India’s Own Monoclonal Antibody.

For the wider view across checkpoint inhibitors and the other medicine classes, start from Immunotherapy Medicines Explained, or from the main immunotherapy section.